SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VVOS

Vivos Therapeutics, Inc. (VVOS)

NASDAQ: VVOS · USD
Healthcare · Medical Devices
$0.08-$0.00 (-4.64%)
 
Market cap
$2.57M
Insider Score
Website
Market Cap$2.57M-96.9%
Revenue (ttm)$20.90M
Net Income-$25.46M
EPS-$1.35
Shares Out33.82M
PE Ration/a
Forward PE-0.09
Dividendn/a
Ex-Dividend Daten/a
Volume1,861,690
Open$0.08
Previous Close$0.08
Day's Range$0.07 - $0.08
52-Week Range$0.07 - $2.69
Beta6.30
Analystsnone
Price Target$1.93(+2432.89%)
Earnings DateNov 16, 2026
+0.38% (1D)
No price history available.

About VVOS

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Address
7921 Southpark Plaza, Littleton, CO, 80120, United States
Market Cap
3 million
Employees
268
Industrial Classification
Medical Devices

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$1.81M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-5.00%
5 Days
-16.48%
1 Month
-46.10%
6 Months
-87.12%
1 Year
-96.92%

$VVOS stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in VVOS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VVOS's directors and management

Net Shares Purchased by Insiders−2M−1M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VVOS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New VVOS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VVOS from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from VVOS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
72

News check: Q3 revenue beat and operational updates suggest positive near-term execution, though loss reported indicates profitability challenges ahead.

Recent Insider Activity

Buys
2
Sells
0
Buy Value
$1.81M
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.